Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

FAS mutations are an uncommon cause of immune thrombocytopenia in children and adults without additional features of immunodeficiency.

Vandrovcova J, Salzer U, Grimbacher B, Wanders J, Rao K, Thrasher A, Burns S, Gilmore K, Bussel J, Cooper N.

Br J Haematol. 2019 Sep;186(6):e163-e165. doi: 10.1111/bjh.15979. Epub 2019 Jun 6. No abstract available.

PMID:
31172514
2.

The combined effect of mammographic texture and density on breast cancer risk: a cohort study.

Wanders JOP, van Gils CH, Karssemeijer N, Holland K, Kallenberg M, Peeters PHM, Nielsen M, Lillholm M.

Breast Cancer Res. 2018 May 2;20(1):36. doi: 10.1186/s13058-018-0961-7.

3.

Mammographic density and ageing: A collaborative pooled analysis of cross-sectional data from 22 countries worldwide.

Burton A, Maskarinec G, Perez-Gomez B, Vachon C, Miao H, Lajous M, López-Ridaura R, Rice M, Pereira A, Garmendia ML, Tamimi RM, Bertrand K, Kwong A, Ursin G, Lee E, Qureshi SA, Ma H, Vinnicombe S, Moss S, Allen S, Ndumia R, Vinayak S, Teo SH, Mariapun S, Fadzli F, Peplonska B, Bukowska A, Nagata C, Stone J, Hopper J, Giles G, Ozmen V, Aribal ME, Schüz J, Van Gils CH, Wanders JOP, Sirous R, Sirous M, Hipwell J, Kim J, Lee JW, Dickens C, Hartman M, Chia KS, Scott C, Chiarelli AM, Linton L, Pollan M, Flugelman AA, Salem D, Kamal R, Boyd N, Dos-Santos-Silva I, McCormack V.

PLoS Med. 2017 Jun 30;14(6):e1002335. doi: 10.1371/journal.pmed.1002335. eCollection 2017 Jun.

4.

Autoantibodies against BAFF, APRIL or IL21 - an alternative pathogenesis for antibody-deficiencies?

Pott MC, Frede N, Wanders J, Hammarström L, Glocker EO, Glocker C, Tahami F, Grimbacher B.

BMC Immunol. 2017 Jun 26;18(1):34. doi: 10.1186/s12865-017-0217-9.

5.

The effect of volumetric breast density on the risk of screen-detected and interval breast cancers: a cohort study.

Wanders JOP, Holland K, Karssemeijer N, Peeters PHM, Veldhuis WB, Mann RM, van Gils CH.

Breast Cancer Res. 2017 Jun 5;19(1):67. doi: 10.1186/s13058-017-0859-9.

6.

Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations.

Hou TZ, Verma N, Wanders J, Kennedy A, Soskic B, Janman D, Halliday N, Rowshanravan B, Worth A, Qasim W, Baxendale H, Stauss H, Seneviratne S, Neth O, Olbrich P, Hambleton S, Arkwright PD, Burns SO, Walker LS, Sansom DM.

Blood. 2017 Mar 16;129(11):1458-1468. doi: 10.1182/blood-2016-10-745174. Epub 2017 Feb 3.

7.

Volumetric breast density affects performance of digital screening mammography.

Wanders JO, Holland K, Veldhuis WB, Mann RM, Pijnappel RM, Peeters PH, van Gils CH, Karssemeijer N.

Breast Cancer Res Treat. 2017 Feb;162(1):95-103. doi: 10.1007/s10549-016-4090-7. Epub 2016 Dec 23.

8.

Mammographic density assessed on paired raw and processed digital images and on paired screen-film and digital images across three mammography systems.

Burton A, Byrnes G, Stone J, Tamimi RM, Heine J, Vachon C, Ozmen V, Pereira A, Garmendia ML, Scott C, Hipwell JH, Dickens C, Schüz J, Aribal ME, Bertrand K, Kwong A, Giles GG, Hopper J, Pérez Gómez B, Pollán M, Teo SH, Mariapun S, Taib NA, Lajous M, Lopez-Riduara R, Rice M, Romieu I, Flugelman AA, Ursin G, Qureshi S, Ma H, Lee E, Sirous R, Sirous M, Lee JW, Kim J, Salem D, Kamal R, Hartman M, Miao H, Chia KS, Nagata C, Vinayak S, Ndumia R, van Gils CH, Wanders JO, Peplonska B, Bukowska A, Allen S, Vinnicombe S, Moss S, Chiarelli AM, Linton L, Maskarinec G, Yaffe MJ, Boyd NF, Dos-Santos-Silva I, McCormack VA.

Breast Cancer Res. 2016 Dec 19;18(1):130.

9.

International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries.

McCormack VA, Burton A, dos-Santos-Silva I, Hipwell JH, Dickens C, Salem D, Kamal R, Hartman M, Lee CP, Chia KS, Ozmen V, Aribal ME, Flugelman AA, Lajous M, Lopez-Riduara R, Rice M, Romieu I, Ursin G, Qureshi S, Ma H, Lee E, van Gils CH, Wanders JO, Vinayak S, Ndumia R, Allen S, Vinnicombe S, Moss S, Won Lee J, Kim J, Pereira A, Garmendia ML, Sirous R, Sirous M, Peplonska B, Bukowska A, Tamimi RM, Bertrand K, Nagata C, Kwong A, Vachon C, Scott C, Perez-Gomez B, Pollan M, Maskarinec G, Giles G, Hopper J, Stone J, Rajaram N, Teo SH, Mariapun S, Yaffe MJ, Schüz J, Chiarelli AM, Linton L, Boyd NF.

Cancer Epidemiol. 2016 Feb;40:141-51. doi: 10.1016/j.canep.2015.11.015. Epub 2015 Dec 24.

10.

The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1.

Depner M, Fuchs S, Raabe J, Frede N, Glocker C, Doffinger R, Gkrania-Klotsas E, Kumararatne D, Atkinson TP, Schroeder HW Jr, Niehues T, Dückers G, Stray-Pedersen A, Baumann U, Schmidt R, Franco JL, Orrego J, Ben-Shoshan M, McCusker C, Jacob CM, Carneiro-Sampaio M, Devlin LA, Edgar JD, Henderson P, Russell RK, Skytte AB, Seneviratne SL, Wanders J, Stauss H, Meyts I, Moens L, Jesenak M, Kobbe R, Borte S, Borte M, Wright DA, Hagin D, Torgerson TR, Grimbacher B.

J Clin Immunol. 2016 Jan;36(1):73-84. doi: 10.1007/s10875-015-0214-9. Epub 2015 Nov 25.

11.

Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.

Elgizouli M, Lowe DM, Speckmann C, Schubert D, Hülsdünker J, Eskandarian Z, Dudek A, Schmitt-Graeff A, Wanders J, Jørgensen SF, Fevang B, Salzer U, Nieters A, Burns S, Grimbacher B.

Clin Exp Immunol. 2016 Feb;183(2):221-9. doi: 10.1111/cei.12706. Epub 2015 Nov 9.

12.

The effect of weight change on changes in breast density measures over menopause in a breast cancer screening cohort.

Wanders JO, Bakker MF, Veldhuis WB, Peeters PH, van Gils CH.

Breast Cancer Res. 2015 May 30;17:74. doi: 10.1186/s13058-015-0583-2.

13.

The effect of out-of-pocket costs and financial rewards in a discrete choice experiment: an application to lifestyle programs.

Wanders JO, Veldwijk J, de Wit GA, Hart HE, van Gils PF, Lambooij MS.

BMC Public Health. 2014 Aug 23;14:870. doi: 10.1186/1471-2458-14-870.

14.

Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.

Muss H, Cortes J, Vahdat LT, Cardoso F, Twelves C, Wanders J, Dutcus CE, Yang J, Seegobin S, O'Shaughnessy J.

Oncologist. 2014 Apr;19(4):318-27. doi: 10.1634/theoncologist.2013-0282. Epub 2014 Mar 28.

15.

Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease.

Frede N, Glocker EO, Wanders J, Engelhardt KR, Kreisel W, Ruemmele FM, Grimbacher B.

BMC Immunol. 2014 Feb 28;15:10. doi: 10.1186/1471-2172-15-10.

16.

A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.

Lesimple T, Edeline J, Carrothers TJ, Cvitkovic F, Darpo B, Delord JP, Léna H, Penel N, Edwards GJ, Law K, Wanders J, Kristensen A, Reyderman L.

Invest New Drugs. 2013 Aug;31(4):900-9. doi: 10.1007/s10637-012-9893-8. Epub 2012 Nov 11.

PMID:
23143778
17.

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.

Devriese LA, Witteveen PO, Marchetti S, Mergui-Roelvink M, Reyderman L, Wanders J, Jenner A, Edwards G, Beijnen JH, Voest EE, Schellens JH.

Cancer Chemother Pharmacol. 2012 Dec;70(6):823-32. doi: 10.1007/s00280-012-1976-x. Epub 2012 Sep 26.

PMID:
23010853
18.

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

Devriese LA, Witteveen PE, Wanders J, Law K, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Huitema AD, Voest EE, Schellens JH.

Br J Clin Pharmacol. 2013 Feb;75(2):507-15. doi: 10.1111/j.1365-2125.2012.04381.x.

19.

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.

Devriese LA, Mergui-Roelvink M, Wanders J, Jenner A, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Schellens JH.

Invest New Drugs. 2013 Apr;31(2):381-9. doi: 10.1007/s10637-012-9829-3. Epub 2012 May 5.

PMID:
22555773
20.

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.

Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O'Brien JP, Schellens JH, Evans TR.

Br J Cancer. 2012 May 8;106(10):1598-604. doi: 10.1038/bjc.2012.154. Epub 2012 Apr 19.

21.

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.

Schöffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, Krarup-Hansen A, Grünwald V, Sciot R, Dumez H, Blay JY, Le Cesne A, Wanders J, Hayward C, Marreaud S, Ouali M, Hohenberger P; European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG).

Lancet Oncol. 2011 Oct;12(11):1045-52. doi: 10.1016/S1470-2045(11)70230-3. Epub 2011 Sep 19. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427.

PMID:
21937277
22.

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

de Bono JS, Molife LR, Sonpavde G, Maroto JP, Calvo E, Cartwright TH, Loesch DM, Feit K, Das A, Zang EA, Wanders J, Agoulnik S, Petrylak DP.

Ann Oncol. 2012 May;23(5):1241-9. doi: 10.1093/annonc/mdr380. Epub 2011 Sep 7.

PMID:
21903605
23.

A woman with recurrent "infections" since birth--a new mevalonate kinase mutation.

Farber CM, Wanders JA, Goffard JC, Parma J.

Acta Clin Belg. 2011 Mar-Apr;66(2):129-31.

PMID:
21630610
24.

Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report.

Boss DS, Glen H, Beijnen JH, de Jong D, Wanders J, Evans TR, Schellens JH.

Tumori. 2011 Jan-Feb;97(1):109-14.

PMID:
21528673
25.

Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices.

Dubbelman AC, Rosing H, Thijssen B, Lucas L, Copalu W, Wanders J, Schellens JH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 May 1;879(15-16):1149-55. doi: 10.1016/j.jchromb.2011.03.021. Epub 2011 Mar 17.

PMID:
21458392
26.

Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.

Keizer RJ, Funahashi Y, Semba T, Wanders J, Beijnen JH, Schellens JH, Huitema AD.

AAPS J. 2011 Jun;13(2):230-9. doi: 10.1208/s12248-011-9260-2. Epub 2011 Mar 9.

27.

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators.

Lancet. 2011 Mar 12;377(9769):914-23. doi: 10.1016/S0140-6736(11)60070-6. Epub 2011 Mar 2.

PMID:
21376385
28.

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA.

J Clin Oncol. 2010 Sep 1;28(25):3922-8. doi: 10.1200/JCO.2009.25.8467. Epub 2010 Aug 2.

PMID:
20679609
29.

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.

Keizer RJ, Gupta A, Mac Gillavry MR, Jansen M, Wanders J, Beijnen JH, Schellens JH, Karlsson MO, Huitema AD.

J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):347-63. doi: 10.1007/s10928-010-9164-2. Epub 2010 Jul 23.

30.

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.

Soto E, Keizer RJ, Trocóniz IF, Huitema AD, Beijnen JH, Schellens JH, Wanders J, Cendrós JM, Obach R, Peraire C, Friberg LE, Karlsson MO.

Invest New Drugs. 2011 Oct;29(5):984-95. doi: 10.1007/s10637-010-9437-z. Epub 2010 May 7.

31.

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.

Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA.

Clin Breast Cancer. 2010 Apr;10(2):160-3. doi: 10.3816/CBC.2010.n.023.

PMID:
20299316
32.

Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820.

Keizer RJ, Zamacona MK, Jansen M, Critchley D, Wanders J, Beijnen JH, Schellens JH, Huitema AD.

Invest New Drugs. 2009 Apr;27(2):140-52. doi: 10.1007/s10637-008-9164-x. Epub 2008 Aug 20.

PMID:
18712503
33.

Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.

Zandvliet AS, Schellens JH, Dittrich C, Wanders J, Beijnen JH, Huitema AD.

Br J Clin Pharmacol. 2008 Oct;66(4):485-97. doi: 10.1111/j.1365-2125.2008.03230.x. Epub 2008 May 29.

34.

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.

Siegel-Lakhai WS, Zandvliet AS, Huitema AD, Tibben MM, Milano G, Girre V, Diéras V, King A, Richmond E, Wanders J, Beijnen JH, Schellens JH.

Br J Cancer. 2008 Apr 22;98(8):1320-6. doi: 10.1038/sj.bjc.6604300. Epub 2008 Apr 15.

35.

A phase I and pharmacokinetic study of indisulam in combination with carboplatin.

Dittrich C, Zandvliet AS, Gneist M, Huitema AD, King AA, Wanders J.

Br J Cancer. 2007 Feb 26;96(4):559-66. Epub 2007 Feb 6.

36.

DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors.

Wente MN, Kleeff J, Büchler MW, Wanders J, Cheverton P, Langman S, Friess H.

Invest New Drugs. 2005 Aug;23(4):339-47.

PMID:
16012793
37.

Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.

de Jonge MJ, van der Gaast A, Planting AS, van Doorn L, Lems A, Boot I, Wanders J, Satomi M, Verweij J.

Clin Cancer Res. 2005 May 15;11(10):3806-13.

38.

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.

van Kesteren C, Zandvliet AS, Karlsson MO, Mathôt RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roché HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JH.

Invest New Drugs. 2005 Jun;23(3):225-34.

PMID:
15868378
39.

Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.

Ravaud A, Cerny T, Terret C, Wanders J, Bui BN, Hess D, Droz JP, Fumoleau P, Twelves C.

Eur J Cancer. 2005 Mar;41(5):702-7.

PMID:
15763645
40.

Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.

Soepenberg O, de Jonge MJ, Sparreboom A, de Bruin P, Eskens FA, de Heus G, Wanders J, Cheverton P, Ducharme MP, Verweij J.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):703-11.

41.

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.

Caponigro F, Willemse P, Sorio R, Floquet A, van Belle S, Demol J, Tambaro R, Comandini A, Capriati A, Adank S, Wanders J.

Invest New Drugs. 2005 Jan;23(1):85-9.

PMID:
15528985
42.

Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755.

Bos AM, Boom K, Vinks AA, Boezen HM, Wanders J, Dombernovsky P, Aamdal S, de Vries EG, Uges DR.

Cancer Chemother Pharmacol. 2004 Jul;54(1):64-70. Epub 2004 Apr 7.

PMID:
15069581
43.

Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.

Schöffski P, Thate B, Beutel G, Bolte O, Otto D, Hofmann M, Ganser A, Jenner A, Cheverton P, Wanders J, Oguma T, Atsumi R, Satomi M.

Ann Oncol. 2004 Apr;15(4):671-9.

PMID:
15033678
44.

Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.

Comets E, Ikeda K, Hoff P, Fumoleau P, Wanders J, Tanigawara Y.

J Pharmacokinet Pharmacodyn. 2003 Aug;30(4):257-83.

45.

Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.

Dittrich C, Dumez H, Calvert H, Hanauske A, Faber M, Wanders J, Yule M, Ravic M, Fumoleau P.

Clin Cancer Res. 2003 Nov 1;9(14):5195-204.

46.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

Twelves C, Hoekman K, Bowman A, Vermorken JB, Anthoney A, Smyth J, van Kesteren C, Beijnen JH, Uiters J, Wanders J, Gomez J, Guzmán C, Jimeno J, Hanauske A.

Eur J Cancer. 2003 Sep;39(13):1842-51.

PMID:
12932661
47.

Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).

Chollet P, Schöffski P, Weigang-Köhler K, Schellens JH, Cure H, Pavlidis N, Grünwald V, De Boer R, Wanders J, Fumoleau P; EORTC Early Clinical Studies Group.

Eur J Cancer. 2003 Jun;39(9):1264-70.

PMID:
12763215
48.

Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.

Peters GJ, Noordhuis P, Van Kuilenburg AB, Schornagel JH, Gall H, Turner SL, Swart MS, Voorn D, Van Gennip AH, Wanders J, Holwerda U, Smid K, Giaccone G, Fumoleau P, Van Groeningen CJ.

Cancer Chemother Pharmacol. 2003 Jul;52(1):1-12. Epub 2003 May 9.

PMID:
12739060
49.

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).

Terret C, Zanetta S, Roché H, Schellens JH, Faber MN, Wanders J, Ravic M, Droz JP; EORTC Early Clinical Study Group.

Eur J Cancer. 2003 May;39(8):1097-104.

PMID:
12736109
50.

EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.

Van den Brande J, Schöffski P, Schellens JH, Roth AD, Duffaud F, Weigang-Köhler K, Reinke F, Wanders J, de Boer RF, Vermorken JB, Fumoleau P.

Br J Cancer. 2003 Mar 10;88(5):648-53.

Supplemental Content

Loading ...
Support Center